{"id":"NCT03897075","sponsor":"Sun Pharmaceutical Industries Limited","briefTitle":"Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-05-13","primaryCompletion":"2024-04-05","completion":"2025-01-30","firstPosted":"2019-04-01","resultsPosted":"2025-06-06","lastUpdate":"2025-06-06"},"enrollment":99,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Plaque Psoriasis","Moderate to Severe Nail Psoriasis"],"interventions":[{"type":"DRUG","name":"Tildrakizumab","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Arm A","type":"EXPERIMENTAL"},{"label":"Arm B","type":"PLACEBO_COMPARATOR"}],"summary":"Phase 3b study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis","primaryOutcome":{"measure":"The Proportion of Subjects Who Achieve at Least a 75% Improvement From Baseline in Total mNAPSI at Week 28.","timeFrame":"Week 28","effectByArm":[{"arm":"Placebo","deltaMin":0.042,"sd":null},{"arm":"Tildrakizumab 100 mg","deltaMin":0.255,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.00311"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":17,"countries":["United States","Australia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":51},"commonTop":["COVID-19","Upper respiratory tract infection","Hypertension","Cellulitis","Urinary tract infection"]}}